Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
MilliporeSigma™ anti-Fibronectin Clone: FBN11,
Mouse Monoclonal Antibody
Supplier: MilliporeSigma™ CP70100UG
Description
Specifically detects Fibronectin Clone: FBN11 in Human, Mouse, Rat samples, and it is validated for Immunofluorescence, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Immunoprecipitation, Immuno Blotting
Fibronectin is a dimeric, disulfide-linked glycoprotein of ∽440kDa that is present in basement membranes, extracellular matrix, and blood. Fibronectin contains multiple sites for various ligands and cells including binding sites for collagen, glycosaminoglycans, transglutaminase, and a cell surface receptor. This glycoprotein is involved in cell adhesion, tissue organization, and wound healing. The region of fibronectin that mediates cell adhesion in a majority of cell types is in the C-terminal domain and involves the binding of the Arg-Gly-Asp (RGD) sequence to a specific polypeptide cell surface receptor. Although the mechanisms of fibronectin extracellular matrix assembly are not well understood, specific antibodies have been used to determine the domains involved in matrix assembly. Cellular fibronectin is widely distributed in the stroma of many malignant tumors.
Specifications
Fibronectin | |
Monoclonal | |
Unconjugated | |
Mouse | |
100 μg | |
Primary | |
Human, Mouse, Rat | |
Purified |
Immunoblot, Immunofluorescence, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Immunoprecipitation | |
FBN11 | |
In 10mM PBS, 0.2% BSA, pH 7.4. | |
recombinant human fibronectin | |
RUO | |
Recognizes the ∽440kDa disulfide-linked, dimeric fibronectin in SWI56 cells and normal kidney tissue. | |
2°C to 8°C | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction